What You Should Know:
– Today, Ultromics, an Oxford, England-based health-tech startup announced it has raised $33M in Series B funding led by Blue Ventures, the investing arm of Blue Cross Blue Shield, and also includes investment from Optum Ventures, GV, and Oxford Sciences.
– Born at the University of Oxford and built-in partnership with the U.K.’s NHS, Ultromics has developed the first fully automated solution for echocardiography and analysis of global longitudinal strain (GLS). Ultromics delivers analysis to any vendor within minutes, with zero variability, without any disruption to workflow, and can even predict a patient’s risk of developing coronary artery disease (CAD). Ultromics has collaborated with leading research institutions, including the American Society of Echocardiography and Mayo Clinic.
– Ultromics will use the new funding to help accelerate the use of AI-enabled echocardiograms to help improve patient care and bring improved diagnostic quality and resource savings to hospitals.
